Faculty Profiles - NAGAO Shoji

MISC - NAGAO Shoji

Division display 81 - 100 of about 131 ／ All the affair displays >>

オープンディスカッション卵巣がん委員会報告 iPocc試験プロトコール概要

長尾昌二

第8回婦人科悪性腫瘍化学療法研究機構年次会議（総会）記録集 158 - 61 2010.1

P1-140 子宮体部病変に対するMRI拡散強調画像を用いたADC値の有用性の検討(Group18 婦人科腫瘍画像診断1,一般演題,第62回日本産科婦人科学会学術講演会)

長谷川幸清, 大石理恵, 岩佐紀宏, 清水基弘, 長尾昌二, 藤原恵一

日本産科婦人科學會雜誌 62 ( 2 ) 395 - 395 2010

上皮性卵巣癌の妊孕性温存療法の適応と限界

長尾昌二, 岩佐紀宏, 藤原恵一

臨床婦人科産科 2009.12

Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer A Sankai Gynecology Cancer Study Group Study International journal

Keiichi Fujiwara, Shoji Nagao, Junzo Kigawa, Jun Noma, Nobuo Akamatsu, Yasunari Miyagi, Fumitaka Numa, Makoto Okada, Eriko Aotani

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 ( 5 ) 834 - 837 2009.7

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

Purpose: To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel.
Patients and Methods: Eligible patients were those with epithelial ovarian carcinoma or primary peritoneal carcinoma stages 11 to IV who underwent initial surgery and had a residual tumor size of 2 cm or larger. Patients received IV paclitaxel 175 mg/m(2) followed by intraperitoneal carboplatin AUC6. The primary end point was a response. Secondary end points were toxicity, progression-free survival, and overall survival.
Results: Twenty-six patients were enrolled, and 24 patients were eligible for assessment. The response rate was 83.3% (95% CI, 62.6%-95.3%; Table 4). The median progression-free survival was 25 months. The median overall survival had not been reached. Incidences of grade (G) 3/4 hematological toxicities were absolute neutrophil count, 96%; hemoglobin, 29%; and thrombocytopenia, 16%. Nonhematological toxicities included G2 liver function, 4%; G3 sensory neuropathy, 8%; and G3 myalgia and arthralgia, 4%.
Conclusions: Intraperitoneal administration of carboplatin combined with IV paclitaxel was well tolerated and showed satisfactory response in the patients with bulky residual tumor. Large-scale phase III trial comparing with IV carboplatin is warranted in this patient population.

DOI： 10.1111/IGC.0b013e3181a29dfe

Web of Science

PubMed

researchmap

Keiichi Fujiwara, Shoji Nagao, Junzo Kigawa, Jun Noma, Nobuo Akamatsu, Yasunari Miyagi, Fumitaka Numa, Makoto Okada, Eriko Aotani

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 ( 5 ) 834 - 837 2009.7

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

DOI： 10.1111/IGC.0b013e3181a29dfe

Web of Science

researchmap

上皮性卵巣がんの妊孕性温存手術

長尾昌二, 大石理恵, 伊藤百合子, 岩佐紀宏, 清水基弘, 後藤友子, 藤原恵一

産科と婦人科 76 ( 4 ) 403 - 8 2009.4

卵巣境界悪性腫瘍の妊孕能温存治療 (特集妊孕能温存の婦人科がん治療)

長尾昌二, 大石理恵, 伊藤百合子

産婦人科の実際 58 ( 3 ) 375 - 381 2009.3

An estimation of total number of cycles of chemotherapy in patients with epithelial ovarian cancer worldwide

S. Nagao, R. Ohishi, N. Iwasa, M. Shimizu, T. Goto, K. Fujiwara

GYNECOLOGIC ONCOLOGY 112 ( 2 ) S56 - S57 2009.2

Is the adjustment of serum creatinine level from < 0.6 mg/dl to 0.6 mg/dl justified in estimating carboplatin clearance calculated by the Jelliffe formula?

Shoji Nagao, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Tomoko Goto, Keiichi Fujiwara

Clinical Ovarian Cancer 2 ( 1 ) 48 - 51 2009

Language：English Publisher：Cancer Information Group, LP

In current Gynecologic Oncology Group studies, serum creatinine level is adjusted to 0.6 mg/dL in patients with levels &lt
0.6 mg/dL (Adjusted-Jelliffe formula). The purpose of this study is to evaluate whether this adjustment is suitable. Patients and Methods: Carboplatin clearance was estimated in 115 patients with serum creatinine &lt
0.6 mg/dL who received carboplatin-based chemotherapy for gynecologic malignancies between January 1996 and August 2004. The clearance was estimated using the Cockroft-Gault, Jelliffe, and Adjusted-Jelliffe formulae. The 3 estimations were then compared with each other using the post hoc Wilcoxon signed rank test. Bias was assessed by mean percentage error (MPE), and precision was assessed by mean absolute percentage error (MAPE). The relationships between body surface area (BSA) and ratios of estimated carboplatin clearance (Jelliffe formula/Cockroft-Gault formula and Adjusted-Jelliffe formula/Cockroft-Gault formula) were evaluated by simple regression analysis. Results: The carboplatin clearance calculated by the Jelliffe formula was significantly larger than the other 2 formulae (P &lt
.0001). Although MPE was reduced from +20 to +6 by adjustment of serum creatinine, MAPE was barely reduced from 21 to 14. The simple regression line represents correlation between BSA and ratios of estimated carboplatin clearance was merely translated to below by adjusting the serum creatinine level, and the bias by BSA was not corrected. Conclusion: Despite adjusting the serum creatinine level, the Adjusted-Jelliffe formula overestimates the creatinine clearance when compared with the Cockcroft-Gault formula.

DOI： 10.3816/COC.2009.n.007

Scopus

researchmap

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer

S. Nagao, K. Fujiwara, R. Ohishi, Y. Nakanishi, N. Iwasa, M. Shimizu, T. Goto, K. Shimoya

International Journal of Gynecological Cancer 18 ( 6 ) 1210 - 1214 2008.11

Language：English

The objective of this study was to retrospectively assess the efficacy and safety of combination chemotherapy of intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel in suboptimally debulked ovarian cancer. Between March 1998 and March 2006, 44 patients with histologically confirmed epithelial ovarian carcinoma or peritoneal carcinoma with a residual mass greater than 1 cm received combination chemotherapy of IV paclitaxel and IP carboplatin. Administration of IV paclitaxel at 175 mg/m2 immediately followed by IP carboplatin at an area under the curve of 6 was scheduled every 3 weeks for at least six cycles. The diagnosis and stage were ovarian carcinoma stage II in 8, III in 25, and IV in 6 cases, and peritoneal carcinoma stage III in 5 cases. Eighty-three percent of patients completed more than six cycles of chemotherapy. The incidences of grade 3/4 hematologic toxicities were 41 (93%) for neutrocytopenia, 10 (41%) for thrombocytopenia, and 18 (23%) for anemia. Observed grade 3/4 nonhematologic toxicities were 1 (2%) for allergy, 1 (2%) for fatigue, 1 (2%) for vomiting, 1 (2%) for liver dysfunction, and 4 (9%) for peripheral neuropathy. Two patients (5%) encountered catheter problems (one obstruction and one infection). Overall response rate was 80% (16 complete response, 19 partial response, 3 stable disease, and 6 progressive disease). Median progression-free survival and overall survival were 24 and 31 months, respectively. Combination chemotherapy of IP carboplatin and IV paclitaxel is effective and safe in suboptimally debulked ovarian cancer, and further evaluation is warranted. © 2008, Copyright the Authors.

DOI： 10.1111/j.1525-1438.2008.01192.x

Scopus

PubMed

researchmap

腹腔内化学療法 (特集婦人科がん診療のリスクマネージメント) -- (化学療法の問題点)

後藤友子, 長尾昌二, 藤原恵一

産婦人科の実際 57 ( 11 ) 1853 - 1856 2008.10

Conservative surgery for ovarian cancer

97 ( 2 ) 149 - 156 2008.8

Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study International journal

Jason D. Wright, Chunqiao Tian, David G. Mutch, Thomas J. Herzog, Shoji Nagao, Keiichi Fujiwara, Matthew A. Powell

GYNECOLOGIC ONCOLOGY 109 ( 3 ) 353 - 358 2008.6

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Background. Carboplatin dosing for gynecologic malignancies is traditionally based on the Jelliffe formula that lacks dose adjustment for weight. Obese women may therefore receive a sub-therapeutic carboplatin dose. This study assessed the association between BM I and outcome for ovarian cancer patients treated with carboplatin-based chemotherapy.
Methods. An analysis of patients treated with carboplatin and paclitaxel on Gynecologic Oncology Group (GOG) protocol 158 was perfonned. The dose of carboplatin for each patient was based on an area under the curve of 7.5 and a glomerular filtration rate (GFR) derived from the Jelliffe formula which is derived from age and serum creatinine. Patients were stratified based on body mass index (BMI).
Results. A total of 387 patients were included in the analysis. The patients were stratified into three groups: normal weight (BMI < 25.0, 50%), overweight (BMI 25-29.9, 32%) and obese (BMI >= 30.0, 18%). Compared to pretreatment values, the obese patients had a lower relative decrease in their platelet counts (- 25% for BMI >= 30 vs. - 6 1% for BMI < 25) (p = 0.01). Similar trends were noted for relative changes in hemoglobin (p = 0.006) and hematocrit (p = 0.002). Dose reductions were required in 34% of normal weight compared to 2 1% of the obese women (p = 0.004). There was a trend toward increased risk for disease progression in women with a BMI >= 30 (RR: 1.25, 95% CI: 0.93-1.69, p = 0. 14).
Conclusion. Obese ovarian cancer patients treated with carboplatin experience substantially less toxicity than normal weight women. The lower toxicity suggests that obese patients may be receiving a substandard drug dose. (c) 2008 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2008.02.023

Web of Science

PubMed

researchmap

上皮性卵巣がんに対するcarboplatin腹腔内投与およびpaclitaxel静脈内点滴投与の有用性

長尾昌二, 大石理恵, 塚本有佳子, 中西美恵, 岩佐紀宏, 清水基弘, 後藤友子, 藤原恵一, 下屋浩一郎

癌の臨床 54 ( 5 ) 1 - 7 2008.5

Combination chemotherapy of intraperitoneal carboplatin and intravenous taxane in advanced endometrial cancer: A pilot study

S. Nagao, R. Oishi, Y. Tsukamoto, Y. Nakanishi, N. Iwasa, M. Shimizu, T. Goto, K. Fujiwara

JOURNAL OF CLINICAL ONCOLOGY 26 ( 15 ) 2008.5